Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack
Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue Biopharma $12 million for a novel preclinical program that could eliminate some of the risks of rival approaches.
Boehringer Ingelheim has joined the surge of companies entering the B-cell depletion space. But while its peers have largely focused on CAR-Ts and bispecifics, the German drugmaker has paid Cue Biopharma $12 million for a novel preclinical program that could eliminate some of the risks of rival approaches.
